Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials

DOI: 10.1007/s10620-011-1906-5
Digestive Diseases and Sciences, 2012, 57, 440-50.

#	Paper	IF	Citations
79	Novel therapeutic/integrative approaches for celiac disease and dermatitis herpetiformis. *Clinical and Developmental Immunology*, **2012**, 2012, 959061		14
78	Recent advances in the development of new treatments for celiac disease. *Expert Opinion on Biological Therapy*, **2012**, 12, 1589-600	5.4	7
77	Non-systemic drugs: a critical review. *Current Pharmaceutical Design*, **2012**, 18, 1434-45	3.3	53
76	Future treatment strategies for celiac disease. *Expert Opinion on Therapeutic Targets*, **2012**, 16, 665-75	6.4	11
75	The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet. *Seminars in Immunopathology*, **2012**, 34, 581-600	12	20
74	Nondietary therapies for celiac disease. *Gastrointestinal Endoscopy Clinics of North America*, **2012**, 22, 811-31	3.3	18
73	Celiac disease: advances in treatment via gluten modification. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 859-62	6.9	38
72	Celiac disease: a challenging disease for pharmaceutical scientists. *Pharmaceutical Research*, **2013**, 30, 619-26	4.5	18
71	Celiac disease. *Oral Diseases*, **2013**, 19, 635-41	3.5	11
70	Latest in vitro and in vivo models of celiac disease. *Expert Opinion on Drug Discovery*, **2013**, 8, 445-57	6.2	20
69	Current trends and investigative developments in celiac disease. *Immunological Investigations*, **2013**, 42, 273-84	2.9	7
68	The burden of celiac disease in Canada: more work needed to lighten the load. *Canadian Journal of Gastroenterology & Hepatology*, **2013**, 27, 448		1
67	Celiac Disease and its Therapy. **2014**, 143-155		2
66	Advances in coeliac disease. *Current Opinion in Gastroenterology*, **2014**, 30, 154-62	3	39
65	Emerging drugs for coeliac disease. *Expert Opinion on Emerging Drugs*, **2014**, 19, 533-44	3.7	3
64	Gluten Metabolism in Humans. **2014**, 157-170		5
63	Advances in the treatment of coeliac disease: an immunopathogenic perspective. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 36-44	24.2	36

62	Improving the stability and activity of oral therapeutic enzymes-recent advances and perspectives. *Pharmaceutical Research*, **2014**, 31, 1099-105	4.5	35
61	Management of celiac disease: beyond the gluten-free diet. *Gastroenterology*, **2014**, 146, 1594-6	13.3	5
60	Current status of drugs in development for celiac disease. *Expert Opinion on Investigational Drugs*, **2014**, 23, 1079-91	5.9	10
59	Effect of Rothia mucilaginosa enzymes on gliadin (gluten) structure, deamidation, and immunogenic epitopes relevant to celiac disease. *American Journal of Physiology - Renal Physiology*, **2014**, 307, G769-76	5.1	19
58	Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. *Gastroenterology*, **2014**, 146, 1649-58	13.3	145
57	Treatment of both native and deamidated gluten peptides with an endo-peptidase from Aspergillus niger prevents stimulation of gut-derived gluten-reactive T cells from either children or adults with celiac disease. *Clinical Immunology*, **2014**, 153, 323-31	9	9
56	Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 273-85	6.1	39
55	A Grounded Guide to Gluten: How Modern Genotypes and Processing Impact Wheat Sensitivity. *Comprehensive Reviews in Food Science and Food Safety*, **2015**, 14, 285-302	16.4	58
54	Non-dietary methods in the treatment of celiac disease. *Przeglad Gastroenterologiczny*, **2015**, 10, 12-7	6	4
53	Ineffective degradation of immunogenic gluten epitopes by currently available digestive enzyme supplements. *PLoS ONE*, **2015**, 10, e0128065	3.7	31
52	Celiac disease: a disorder emerging from antiquity, its evolving classification and risk, and potential new treatment paradigms. *Gut and Liver*, **2015**, 9, 28-37	4.8	17
51	Immunopathology of Celiac Disease. **2015**, 1551-1572		
50	Emerging drugs for celiac disease. *Expert Opinion on Emerging Drugs*, **2015**, 20, 129-35	3.7	5
49	The present and the future in the diagnosis and management of celiac disease. *Gastroenterology Report*, **2015**, 3, 3-11	3.3	81
48	Coeliac disease and gluten-related disorders in childhood. *Nature Reviews Gastroenterology and Hepatology*, **2015**, 12, 527-36	24.2	38
47	Celiac disease 2015 update: new therapies. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 913-27	4.2	18
46	Therapeutic approaches for celiac disease. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2015**, 29, 503-21	2.5	37
45	Novel treatments for celiac disease: glutenases and beyond. *Digestive Diseases*, **2015**, 33, 277-281	3.2	15

44	High adherence to a gluten-free diet in adolescents with screening-detected celiac disease. *Journal of Pediatric Gastroenterology and Nutrition*, **2015**, 60, 54-9	2.8	29
43	Editorial: enhancing gluten digestion in the stomach - a further help to minimise unintentional ingestion?. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 484	6.1	0
42	Engineering of Kuma030: A Gliadin Peptidase That Rapidly Degrades Immunogenic Gliadin Peptides in Gastric Conditions. *Journal of the American Chemical Society*, **2015**, 137, 13106-13	16.4	65
41	Identification and characterization of intestinal lactobacilli strains capable of degrading immunotoxic peptides present in gluten. *Journal of Applied Microbiology*, **2015**, 118, 515-27	4.7	20
40	Identification of food-grade subtilisins as gluten-degrading enzymes to treat celiac disease. *American Journal of Physiology - Renal Physiology*, **2016**, 311, G571-80	5.1	12
39	Current Status of Celiac Disease Drug Development. *American Journal of Gastroenterology*, **2016**, 111, 779-86	0.7	15
38	Serum I-FABP Detects Gluten Responsiveness in Adult Celiac Disease Patients on a Short-Term Gluten Challenge. *American Journal of Gastroenterology*, **2016**, 111, 1014-22	0.7	31
37	Addressing proteolytic efficiency in enzymatic degradation therapy for celiac disease. *Scientific Reports*, **2016**, 6, 30980	4.9	38
36	Current and novel therapeutic strategies in celiac disease. *Expert Review of Clinical Pharmacology*, **2016**, 9, 1211-23	3.8	20
35	Immunopathogenesis and therapeutic approaches in pediatric celiac disease. *Expert Review of Clinical Immunology*, **2016**, 12, 857-69	5.1	1
34	Celiac Disease and Drug-Based Therapies: Inquiry into Patients Demands. *Digestion*, **2016**, 93, 160-6	3.6	13
33	Gluten-related disorders: certainties, questions and doubts. *Annals of Medicine*, **2017**, 49, 569-581	1.5	22
32	Celiac Disease. **2017**, 475-526		
31	New Insights into the Pathogenesis of Celiac Disease. *Frontiers in Medicine*, **2017**, 4, 137	4.9	34
30	Celiac disease: From pathophysiology to treatment. *World Journal of Gastrointestinal Pathophysiology*, **2017**, 8, 27-38	3.2	94
29	Next-generation therapies for celiac disease: The gluten-targeted approaches. *Trends in Food Science and Technology*, **2018**, 75, 56-71	15.3	30
28	Autoimmune phenotypes in schizophrenia reveal novel treatment targets. *Pharmacology & Therapeutics*, **2018**, 189, 184-198	13.9	18
27	Green Tea Polyphenols Mitigate Gliadin-Mediated Inflammation and Permeability in Vitro. *Molecular Nutrition and Food Research*, **2018**, 62, e1700879	5.9	19

26	Celiac Disease: Historical Standpoint, New Perspectives of Treatments and Contemporary Research Techniques. *Current Protein and Peptide Science*, **2018**, 19, 1058-1070	2.8	0
25	Challenges to drug discovery for celiac disease and approaches to overcome them. *Expert Opinion on Drug Discovery*, **2019**, 14, 957-968	6.2	4
24	Novel Nondietary Therapies for Celiac Disease. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 8, 335-345	7.9	22
23	Development of wheat genotypes expressing a glutamine-specific endoprotease from barley and a prolyl endopeptidase from Flavobacterium meningosepticum or Pyrococcus furiosus as a potential remedy to celiac disease. *Functional and Integrative Genomics*, **2019**, 19, 123-136	3.8	16
22	Nondietary Therapies for Celiac Disease. *Gastroenterology Clinics of North America*, **2019**, 48, 145-163	4.4	24
21	Celiac Disease and Non-celiac Wheat Sensitivity: State of Art of Non-dietary Therapies. *Frontiers in Nutrition*, **2020**, 7, 152	6.2	6
20	Pathogenesis of Celiac Disease and Other Gluten Related Disorders in Wheat and Strategies for Mitigating Them. *Frontiers in Nutrition*, **2020**, 7, 6	6.2	46
19	Current and emerging therapies for coeliac disease. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 181-195	24.2	20
18	Celiac Disease. **2021**, 356-364.e3		
17	Gliadin Sequestration as a Novel Therapy for Celiac Disease: A Prospective Application for Polyphenols. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
16	Efficient Hydrolysis of Gluten-Derived Celiac Disease-Triggering Immunogenic Peptides by a Bacterial Serine Protease from. *Biomolecules*, **2021**, 11,	5.9	2
15	Gluten Degradation, Pharmacokinetics, Safety, and Tolerability of TAK-062, an Engineered Enzyme to Treat Celiac Disease. *Gastroenterology*, **2021**, 161, 81-93.e3	13.3	11
14	Current pharmacological approaches and potential future therapies for Celiac disease. *European Journal of Pharmacology*, **2021**, 909, 174434	5.3	1
13	Health Hazards Associated with Wheat and Gluten Consumption in Susceptible Individuals and Status of Research on Dietary Therapies. **2020**, 471-515		3
12	Celiac Disease. **2016**, 453-469		1
11	Non-dietary forms of treatment for adult celiac disease. *World Journal of Gastrointestinal Pharmacology and Therapeutics*, **2013**, 4, 108-12	3	8
10	Effective Degradation of Gluten and Its Fragments by Gluten-Specific Peptidases: A Review on Application for the Treatment of Patients with Gluten Sensitivity. *Pharmaceutics*, **2021**, 13,	6.4	4
9	Celiac Disease as a Model Disorder for Testing Novel Autoimmune Therapeutics. **2014**, 126-139		

8	Celiac Disease. 1264-1275	
7	Celiac disease - diangostics, therapy, risk of cancer. *Onkologie (Czech Republic)*, **2018**, 12, 293-296	0.1
6	New Therapeutic Strategies in Celiac Disease. **2022**, 171-191	
5	Use of a proline-specific endopeptidase to reintroduce gluten in patients with non-coeliac gluten sensitivity: A randomized trial. **2022**, 41, 2025-2030	0
4	Crystal structure of a Burkholderia peptidase and modification of the substrate-binding site for enhanced hydrolytic activity toward gluten-derived pro-immunogenic peptides. **2022**,	0
3	Novel Drug Therapeutics in Celiac Disease: A Pipeline Review.	0
2	Celiac Disease: Disease Models in Understanding Pathogenesis and Search for Therapy. **2022**, 10, 705-719	0
1	Novel Therapies for Celiac Disease: A Clinical Review Article. **2023**,	0